Ultragenyx (RARE) Q2 FY26 earnings call

Ultragenyx delivered strong Q2 FY26 results, driven by robust commercial execution across its product portfolio, leading to record quarterly revenue. The company is actively preparing for the potential launches of two gene therapies, DTX401 and UX111, following their upcoming PDUFA dates, and anticipates top-line Phase III data for GTX-102 in Angelman syndrome. Despite a setback in the setrusumab program, management reaffirmed its full-year guidance and remains confident in its path to profitability by 2027, supported by continued growth and disciplined expense management.